Twist Bioscience (TWST) Net Income towards Common Stockholders (2017 - 2026)

Twist Bioscience has disclosed Net Income towards Common Stockholders across 10 years of filings, most recently posting -$44.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 11.86% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$81.3 million (up 57.49% YoY), while the FY2025 annual figure was -$77.7 million, up 62.8% from the prior year.
• Net Income towards Common Stockholders slipped to -$44.0 million in Q1 2026, from -$30.5 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for TWST reached as high as $20.4 million in Q2 2025 and fell as low as -$85.6 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is -$44.0 million (2026), against an average of -$43.4 million.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 59.99% — and 2025, when it surged 123.82%.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$41.8 million in 2022, then slipped by 2.83% to -$43.0 million in 2023, then gained by 26.53% to -$31.6 million in 2024, then advanced by 3.45% to -$30.5 million in 2025, then tumbled by 44.3% to -$44.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$44.0 million, -$30.5 million, and -$27.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.